Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | MIF | P14174 | 3/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545646 | 0.83 | CCR2 (0.41) | CCR2KCNH2HRH3DRD3PDK1 | |
| SCHEMBL12313691 | 0.82 | CCR2 (0.40) | CCR2KCNH2HRH3DRD3PDK1 | |
| SCHEMBL7920193 | 0.80 | BRD4 (0.45) | HRH3BRD4PDK1MIFHDAC6 | |
| SCHEMBL24530509 | 0.79 | CCR2 (0.39) | CCR2KCNH2HRH3DRD3KDM4E | |
| SCHEMBL12313383 | 0.78 | KDM4E (0.41) | CCR2KCNH2HRH3DRD3KDM4E | |
| SCHEMBL12337429 | 0.78 | CCR2 (0.39) | CCR2KCNH2PDK1KDM4EALDH1A1 | |
| SCHEMBL22727773 | 0.77 | BRD4 (0.36) | BRD4PDK1MIFHDAC6GLA | |
| SCHEMBL12312337 | 0.77 | EPHX2 (0.36) | BRD4PDK1KDM4EALDH1A1MIF | |
| SCHEMBL12312372 | 0.76 | KDM4E (0.43) | CCR2KCNH2HRH3DRD3KDM4E | |
| SCHEMBL12625292 | 0.76 | KDM4E (0.43) | CCR2KCNH2HRH3DRD3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | CCR2 2976/4885KCNH2 4559/4885HRH3 3131/4885 |
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | CCR2 2976/4885KCNH2 4559/4885HRH3 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.